

Leishmaniasis treatment using Triazole-phthalimides as chemotherapeutic agents

Problem

The different clinical forms of leishmaniasis (cutaneous, mucocutaneous, and visceral) share a common treatment approach involving toxic chemotherapy and serious side effects, leading to the development of treatment resistance. Thus, the search for more specific drugs against parasites, without causing harm to the host, is still needed.

Solution

The technology relies on the use of molecules containing the compounds triazole and phthalimide, obtained through a cheap and high-yield method, as leishmanicidal agents for the treatment of leishmaniasis. The combination of molecules with different modes of action into a single chemical entity can reduce the side effects and the emergence of resistance, observed in conventional medications against leishmaniasis.


Differential

Reduced toxicity

Less chance of developing resistance

Cheap and efficient synthesis

Development stage



What we are searching for

Partners to advance through the stages of pre-clinical and clinical studies of the technology and in obtaining the molecule on a large scale.


WANT MORE INFORMATION? CONTACT US!

Inventors

Regina Celia Bressan Queiroz de Figueiredo

Intellectual Property

Type
Invention Patent

 Description
Patent application submitted in Brazil.

[ACCESS PATENT DOCUMENT](#)



Use your phone camera to scan
the QR Code:



Campus Fiocruz Maré - Av. Brasil, 4036 - Maré, Rio de Janeiro
- RJ

CEP: 21040-361



portfolio@fiocruz.br



+55 (21) 3282-9080